^
Association details:
| Biomarker: | MRPS9-ALK fusion |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Alecensa (alectinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Novel MRPS9-ALK Fusion Mutation in a Lung Adenocarcinoma Patient: A Case Report
Published date:
06/08/2021
Excerpt:
In this study, a case of lung adenocarcinoma harboring a novel MRPS9-ALK fusion is reported...At last follow-up, over 21 months of overall survival (OS) has been achieved since ALK-TKI treatment. The progression-free survival (PFS) is already ten months since alectinib....The case presented here provides first clinical evidence of the efficacy of ALK-TKIs in NSCLC patients with MRPS9-ALK fusion.
DOI:
10.3389/fonc.2021.670907
